The significant elevation in IGF-1 in the autism group and the reduced proBDNF immunoreactivity in medicated subjects with autism compared to controls reinforces the involvement of those two growth factors in the pathophysiology and treatment of autism. This evidence concerns the gene IGF1 and autism.